Nuance Spectra System

Nuance 光谱系统

• 批准号: 7794365
• 负责人: ROBERT J DISTEL
• 金额: $ 27.93万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-15 至 2011-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794365
• 关键词: Arts; Blood; Blood Circulation; Brain Neoplasms; Cancer Etiology; Cancer Patient; Cells; Chromosome abnormality; Clinical; Clinical Investigator; Communities; Computer software; Dana-Farber Cancer Institute; Disease; Doctor of Philosophy; Drug Monitoring; Drug resistance; Funding; Genetically Engineered Mouse; Grant; Hand; Housing; Image; Institutes; Investigation; Laboratories; Lead; Learning; Link; Lung Neoplasms; Magnetism; Malignant Neoplasms; Methods; Mission; Monitor; Mutagens; National Coalition for Cancer Research; Nature; Pathologist; Pathway interactions; Patients; Pharmacodynamics; Population; Research Personnel; Resistance; Sampling; Scanning; Science; Scientist; Scourge; Signal Transduction; Slide; Solid Neoplasm; System; Therapeutic; Translational Research; Translations; Tumor Burden; Tumor Stem Cells; Work; antibody conjugate; anticancer research; base; bench to bedside; cellular imaging; design; drug discovery; instrument; medical schools; minimally invasive; neoplastic cell; particle; pre-clinical; protein expression; resistance mechanism; response; tumor

DESCRIPTION (provided by applicant): The purpose of this application is to request NCCR SIG funding for a VectraTM slide scanning system to be housed in the Translational Research Laboratory (TRL) in the Center for Clinical and Translational Research at the Dana-Farber Cancer Institute (DFCI). Designed as an engine for translation, moving science from the bench to the bedside and more important the bedside to the bench, the TRL by nature collaborates with many scientists across the institute and the Harvard Medical School community. The system requested has state of the art imaging and software that optimizes information from IHC, IF, HC, FISH and allows multiplexing with all these methods. For cancer research where patient solid tumor samples are difficult to obtain, multispectral analysis offers the possibilities for multiplexing that are impossible with standard RGB system. Most pressing for the TRL is the ability to analyze the rare circulating tumor cells that we capture with antibodies conjugated to magnetic particles. The VectraTM slide scanning system will facilitate the continuing mission of the TRL to make available to DFCI clinical investigators and their collaborators minimally invasive methods to detect, monitor and evaluate patient cancer by sampling and imaging cells shed into the circulation by the solid tumor. The advanced imaging provided by this system will make it possible to routinely detect key chromosomal aberrations that are linked to resistance to targeted agents, evaluate signal transduction and protein expression in response to targeted drugs and monitor overall tumor burden all from the same sample. This multiplexing is required because circulating tumors cells are rare and a single blood draw can yield as few as 10 cells. The ability to monitor the disease in this fashion is essential for understanding the biologic basis for drug resistance mechanisms and identifying appropriate patients for treatment. This will facilitate drug discovery efforts and understanding how to best use targeted cancer therapeutics. The TRL works with preclinical scientists to discover and validate pharmacodynamic markers. Kwok- Kin Wong MD PhD has developed genetically engineered mice that spontaneously form lung tumors. Charles Stiles PhD has found a pathway that makes the rare populations of brain tumor stem cells resistant to genotoxic agents. The multispectral imaging allows quantitative analysis of theses tumor samples, and the multiplexed analysis of rare subsets of tumor stem cells. In addition, the sophisticated learning software puts the power of pathologists in the hands of basic scientists. The grant describes the capabilities of the VectraTM slide scanning system and how the instrument would enhance the overall quality and efficiency of clinical and translational researcher investigations and lead to tangible reduction in the suffering caused by the cancer scourge.

描述（由申请人提供）：本申请的目的是请求 NCCR SIG 资助用于 Dana-Farber 癌症研究所临床和转化研究中心转化研究实验室 (TRL) 的 VectraTM 载玻片扫描系统（DFCI）。 TRL 被设计为翻译引擎，将科学从实验室转移到临床，更重要的是从床边转移到实验室，本质上与该研究所和哈佛医学院社区的许多科学家合作。所要求的系统具有最先进的成像和软件，可优化来自 IHC、IF、HC、FISH 的信息，并允许使用所有这些方法进行多重分析。对于难以获取患者实体瘤样本的癌症研究，多光谱分析提供了标准 RGB 系统无法实现的多重分析的可能性。 TRL 最紧迫的是能够分析我们用与磁性颗粒结合的抗体捕获的罕见循环肿瘤细胞。 VectraTM 玻片扫描系统将促进 TRL 的持续使命，为 DFCI 临床研究人员及其合作者提供微创方法，通过对实体瘤流入循环中的细胞进行采样和成像来检测、监测和评估患者癌症。该系统提供的先进成像技术将能够常规检测与靶向药物耐药性相关的关键染色体畸变，评估针对靶向药物的信号转导和蛋白质表达，并监测来自同一样本的总体肿瘤负荷。这种多重分析是必要的，因为循环肿瘤细胞很少，单次抽血只能产生 10 个细胞。以这种方式监测疾病的能力对于了解耐药机制的生物学基础和确定合适的治疗患者至关重要。这将促进药物发现工作并了解如何最好地使用靶向癌症疗法。 TRL 与临床前科学家合作发现和验证药效标记物。 Kwok-Kin Wong 医学博士已培育出可自发形成肺部肿瘤的基因工程小鼠。查尔斯·斯蒂尔斯博士发现了一种途径，可以使稀有的脑肿瘤干细胞群体对基因毒性药物产生抵抗力。多光谱成像可以对这些肿瘤样本进行定量分析，并对罕见的肿瘤干细胞亚群进行多重分析。此外，先进的学习软件将病理学家的力量交到了基础科学家的手中。 该赠款描述了 VectraTM 玻片扫描系统的功能，以及该仪器如何提高临床和转化研究人员调查的整体质量和效率，并切实减少癌症祸害造成的痛苦。